MAM
SUPN icon

Martingale Asset Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Martingale Asset Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.46M Buy
74,348
+6,800
+10% +$327K 0.08% 257
2026
Q1 		$3.49M Buy
67,548
+9,280
+16% +$473K 0.09% 222
2025
Q4 		$2.9M Sell
58,268
-1,685
-3% -$81.9K 0.07% 245
2025
Q3 		$2.87M Sell
59,953
-4,840
-7% -$195K 0.07% 238
2025
Q2 		$2.04M Buy
64,793
+7,594
+13% +$243K 0.05% 301
2025
Q1 		$1.87M Buy
57,199
+12,607
+28% +$447K 0.05% 311
2024
Q4 		$1.61M Buy
44,592
+6,796
+18% +$239K 0.04% 357
2024
Q3 		$1.18M Buy
37,796
+1,660
+5% +$51.8K 0.03% 421
2024
Q2 		$967K Hold
36,136
– – 0.02% 450
2024
Q1 		$1.23M Hold
36,136
– – 0.02% 422
2023
Q4 		$1.05M Sell
36,136
-12,000
-25% -$318K 0.02% 439
2023
Q3 		$1.33M Hold
48,136
– – 0.03% 358
2023
Q2 		$1.45M Buy
48,136
+1,901
+4% +$66.5K 0.03% 346
2023
Q1 		$1.68M Buy
46,235
+200
+0.4% +$7.69K 0.03% 309
2022
Q4 		$1.64M Sell
46,035
-2,733
-6% -$95K 0.03% 315
2022
Q3 		$1.65M Buy
48,768
+3,800
+8% +$124K 0.03% 291
2022
Q2 		$1.3M Buy
44,968
+2,951
+7% +$84.5K 0.02% 389
2022
Q1 		$1.36M Sell
42,017
-3,755
-8% -$115K 0.02% 401
2021
Q4 		$1.34M Buy
45,772
+36,871
+414% +$1.12M 0.02% 411
2021
Q3 		$238K Buy
+8,901
New +$239K ﹤0.01% 791
2021
Q2 		– Sell
-22,221
Closed -$582K – 894
2021
Q1 		$582K Sell
22,221
-20,127
-48% -$563K 0.01% 568
2020
Q4 		$1.07M Sell
42,348
-15,100
-26% -$325K 0.01% 425
2020
Q3 		$1.2M Buy
57,448
+24,735
+76% +$561K 0.01% 581
2020
Q2 		$777K Buy
+32,713
New +$723K 0.01% 792
2019
Q1 		– Sell
-14,611
Closed -$486K – 1056
2018
Q4 		$486K Buy
14,611
+500
+4% +$21.5K 0.01% 861
2018
Q3 		$711K Sell
14,111
-1,411
-9% -$69.7K 0.01% 785
2018
Q2 		$929K Buy
+15,522
New +$804K 0.01% 758
2015
Q3 		– Sell
-12,912
Closed -$220K – 883
2015
Q2 		$220K Buy
+12,912
New +$184K 0.01% 822

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Martingale Asset Management's SUPN Position: Q2 2026 in Review

Martingale Asset Management increased its Supernus Pharmaceuticals (SUPN) stake by 10% in Q2 2026, buying an estimated $327K and bringing the position to 74,348 shares worth $3.46M. The position accounts for 0.08% of the portfolio, ranked #257.

Martingale Asset Management first reported a position in SUPN in Q2 2015 and has held it in 28 quarters since. The position peaked at $3.49M in Q1 2026. 332 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Martingale Asset Management held 74,348 shares of Supernus Pharmaceuticals worth $3.46M as of Q2 2026.
  • Martingale Asset Management bought 6,800 Supernus Pharmaceuticals shares in Q2 2026, an estimated $327K.
  • Supernus Pharmaceuticals made up 0.08% of Martingale Asset Management's portfolio in Q2 2026, its #257 holding.
  • Martingale Asset Management first reported a position in Supernus Pharmaceuticals in Q2 2015 and has held it in 28 quarters since.
  • Martingale Asset Management's Supernus Pharmaceuticals position peaked at $3.49M in Q1 2026.
  • 332 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Martingale Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.